Highlighted Text:
Show |
Hide
Full text loading...
Chapter 125 : Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis
Authors:
A. Bernard Collins,
Robert B. Colvin
Content Type: Reference
Publication Year:
2006
Category: Immunology
Book DOI:
10.1128/9781555815905
Chapter DOI:
10.1128/9781555815905.ch125
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Preview this chapter:
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap125-1.gif /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap125-2.gif
Abstract:
Several diseases of the kidney with overlapping histological and clinical features are characterized by a rapid loss of renal function, crescentic glomerulonephritis, and sometimes lung hemorrhage. Serological assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-glomerular basement membrane (anti-GBM) autoantibodies are important diagnostic tools in the evaluation of patients with rapidly progressive renal failure and/or pulmonary hemorrhage, providing a rapid noninvasive method for establishing a diagnosis. These tests are sensitive and highly specific and can provide definitive diagnostic information for the effective clinical management of patients with a rapidly progressive course of disease. This chapter describes the detection of circulating anti-GBM antibodies by serological techniques, including Western blot analysis and enzyme-linked immunosorbent assay (ELISA).
Citation:
Collins A, Colvin R.
2006.
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis,
p 1110-1115.
In
Detrick B, Hamilton R, Folds J (ed),
Manual of Molecular and Clinical Laboratory Immunology, 7th Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815905.ch125
Figures
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815905.ch125-1,webId=/content/author/10.1128/9781555815905.ch125-1,properties={foaf_givenname=A. Bernard, foaf_name=A. Bernard Collins, foaf_surname=Collins}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815905.ch125-2,webId=/content/author/10.1128/9781555815905.ch125-2,properties={foaf_givenname=Robert B., foaf_name=Robert B. Colvin, foaf_surname=Colvin}]]
Citation:
Collins A, Colvin R.
2006.
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis,
p 1110-1115.
In
Detrick B, Hamilton R, Folds J (ed),
Manual of Molecular and Clinical Laboratory Immunology, 7th Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815905.ch125
/content/10.1128/9781555815905.ch125.ch125fig01
FIGURE 1
Western blot analysis of a serum sample from an Alport syndrome patient who developed posttransplant anti-GBM nephritis (lane 1). The reactivity of the antibody is to the α3(IV) chain, the Goodpasture antigen, at 28 and 48 to 50 kDa. The reactivity is identical to that seen with a monoclonal antibody to the α3(IV) collagen chain (lane 2) and with that of a serum from a patient with renal-biopsy-proven Goodpasture syndrome (lane 3).
10.1128/9781555815905/f1111-01_thmb.gif
10.1128/9781555815905/f1111-01.gif
FIGURE 1
Western blot analysis of a serum sample from an Alport syndrome patient who developed posttransplant anti-GBM nephritis (lane 1). The reactivity of the antibody is to the α3(IV) chain, the Goodpasture antigen, at 28 and 48 to 50 kDa. The reactivity is identical to that seen with a monoclonal antibody to the α3(IV) collagen chain (lane 2) and with that of a serum from a patient with renal-biopsy-proven Goodpasture syndrome (lane 3).
Citation:
Collins A, Colvin R.
2006.
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis,
p 1110-1115.
In
Detrick B, Hamilton R, Folds J (ed),
Manual of Molecular and Clinical Laboratory Immunology, 7th Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815905.ch125
/content/10.1128/9781555815905.ch125.ch125fig02
FIGURE 2
Western blot analysis of another serum sample from an Alport syndrome patient who also developed post-transplant anti-GBM nephritis. However, when immunoblotted on the collagenase digest of the human GBM it shows reactivity to a lower-molecular-mass antigen in the monomer region of the NC1 domain, at approximately 26 kDa instead of 28 kDa (lane 3). It shows the same reactivity to a higher-molecular-mass antigen in the dimer region, at approximately 48 to 50 kDa. The reactivity is to α5(IV) chain collagen and is identical to reactivity of a monoclonal antibody to the α5(IV) chain collagen (lane 2). Serum from a patient with renal-biopsy-proven Goodpasture syndrome is in lane 1.
10.1128/9781555815905/f1111-02_thmb.gif
10.1128/9781555815905/f1111-02.gif
FIGURE 2
Western blot analysis of another serum sample from an Alport syndrome patient who also developed post-transplant anti-GBM nephritis. However, when immunoblotted on the collagenase digest of the human GBM it shows reactivity to a lower-molecular-mass antigen in the monomer region of the NC1 domain, at approximately 26 kDa instead of 28 kDa (lane 3). It shows the same reactivity to a higher-molecular-mass antigen in the dimer region, at approximately 48 to 50 kDa. The reactivity is to α5(IV) chain collagen and is identical to reactivity of a monoclonal antibody to the α5(IV) chain collagen (lane 2). Serum from a patient with renal-biopsy-proven Goodpasture syndrome is in lane 1.
Citation:
Collins A, Colvin R.
2006.
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis,
p 1110-1115.
In
Detrick B, Hamilton R, Folds J (ed),
Manual of Molecular and Clinical Laboratory Immunology, 7th Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815905.ch125
/content/10.1128/9781555815905.ch125.ch125fig03
FIGURE 3
Western blot analysis of sera from seven patients with biopsy-proven anti-GBM nephritis (lanes 3 to 8). Note the reduced intensity of the bands in lane 7 compared to lane 8. The serum sample in lane 7 was from the same patient as that in lane 8, but after 11 plasmapheresis exchanges. Positive control serum and normal control serum are in lanes 1 and 2, respectively. The antigen preparation is a collagenase digest of human GBM, which is separated by PAGE and immunoblotted onto nitrocellulose paper. The reactivity seen in the positive sera is to the same two molecular mass regions at 28 and 50 kDa, which represent the a3(IV) NC1 (Goodpasture antigen) in its monomeric and dimeric forms.
10.1128/9781555815905/f1113-01_thmb.gif
10.1128/9781555815905/f1113-01.gif
FIGURE 3
Western blot analysis of sera from seven patients with biopsy-proven anti-GBM nephritis (lanes 3 to 8). Note the reduced intensity of the bands in lane 7 compared to lane 8. The serum sample in lane 7 was from the same patient as that in lane 8, but after 11 plasmapheresis exchanges. Positive control serum and normal control serum are in lanes 1 and 2, respectively. The antigen preparation is a collagenase digest of human GBM, which is separated by PAGE and immunoblotted onto nitrocellulose paper. The reactivity seen in the positive sera is to the same two molecular mass regions at 28 and 50 kDa, which represent the a3(IV) NC1 (Goodpasture antigen) in its monomeric and dimeric forms.
Citation:
Collins A, Colvin R.
2006.
Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis,
p 1110-1115.
In
Detrick B, Hamilton R, Folds J (ed),
Manual of Molecular and Clinical Laboratory Immunology, 7th Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815905.ch125
References
/content/book/10.1128/9781555815905.ch125
1.
Barker, D. F.,, S. L. Hostikka,, J. Zhou,, L. T. Chow,, A. R. Oliphant,, S. C. Gerken,, M. C. Gregory,, M. H. Skolnick,, C. L. Atkin, and , K. Tryggvason. 1990. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248: 1224– 1227.
2.
Bosch, X.,, E. Mirapeix,, J. Font,, X. Borrellas,, R. Rodriguez,, A. Lopez-Soto,, M. Ingelmo, and , L. Revert. 1991. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin. Nephrol. 36: 107– 113.
3.
Brainwood, D.,, C. Kashtan,, M. C. Gubler, and , A. N. Turner. 1998. Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int. 53: 762– 766.
4.
Burnette, W. N. 1981. “Western blotting": electro-phoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112: 195– 203.
5.
Bygren, P.,, B. Cederholm,, D. Heinegard, and , J. Wieslander. 1989. Non-Goodpasture anti-GBM antibodies in patients with glomerulonephritis. Nephrol. Dial. Transplant. 4: 254– 261.
6.
Couser, W. G. 1992. Glomerular disorders, p. 551– 568. In J. B. Wyngaarden,, L. H. Smith, and , C. J. Bennett (ed.), Cecil Textbook of Medicine. W. B. Saunders, Philadelphia, Pa.
7.
Edgington, T. S.,, R. J. Glassock,, J. I. Watson, and , F. J. Dixon. 1967. Characterization and isolation of specific renal tubular epithelial antigens. J. Immunol. 99: 1199– 1210.
8.
Gang, N. F. 1970. A rapid method for the isolation of glomeruli from the human kidney. Am. J. Clin. Pathol. 53: 267– 269.
9.
Glassock, R. J.,, A. H. Cohen,, S. G. Adler, and , H. J. Ward. 1991. Secondary glomerular diseases, p. 1280– 1368. In B. M. Brenner and , F. C. Rector (ed.), The Kidney, 4th ed. W. B. Saunders, Philadelphia. Pa.
10.
Hellmark, T.,, C. Johansson, and , J. Wieslander. 1994. Characterization of anti-GBM antibodies involved in Goodpasture’s syndrome. Kidney Int. 46: 823– 829.
11.
Hostikka, S. L.,, R. L. Eddy,, M. G. Byers,, M. Hoyhtya,, T. B. Shows, and , K. Tryggvason. 1990. Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome. Proc. Natl. Acad. Sci. USA 87: 1606– 1610.
12.
Hudson, B. G.,, K. Tryggvason,, M. Sundaramoorthy, and , E. G. Neilson. 2003. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N. Engl. J. Med. 348: 2543– 2556.
13.
Hudson, B. G.,, J. Wieslander,, B. J. Wisdom, Jr., and , M. E. Noelken. 1989. Goodpasture syndrome: molecular architecture and function of basement membrane antigen. Lab. Investig. 61: 256– 269. ( Erratum, 61: 690.)
14.
Jayne, D. R.,, P. D. Marshall,, S. J. Jones, and , C. M. Lockwood. 1990. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 37: 965– 970.
15.
Jenis, E. H.,, J. E. Valeski, and , P. L. Calcagno. 1981. Variability of anti-GBM binding in hereditary nephritis. Clin. Nephrol. 15: 111– 114.
16.
Jennette, J. C.,, A. S. Wilkman, and , R. J. Falk. 1989. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am. J. Pathol. 135: 921– 930.
17.
Johnson, G. D.,, R. S. Davidson,, K. C. McNamee,, G. Russell,, D. Goodwin, and , E. J. Holborow. 1982. Fading of immunofluorescence during microscopy: a study of the phenomenon and its remedy. J. Immunol. Methods 55: 231– 242.
18.
Kalluri, R.,, S. Gunwar,, S. T. Reeders,, K. C. Morrison,, M. Mariyama,, K. E. Ebner,, M. E. Noelken, and , B. G. Hudson. 1991. Goodpasture syndrome. Localization of the epitope for the autoantibodies to the carboxyl-terminal region of the alpha 3(IV) chain of basement membrane collagen. J. Biol. Chem. 266: 24018– 24024.
19.
Kalluri, R.,, M. Weber,, K. O. Netzer,, M. J. Sun,, E. G. Neilson, and , B. G. Hudson. 1994. COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int. 45: 721– 726.
20.
Kashtan, C. E.,, R. J. Butkowski,, M. M. Kleppel,, M. R. First, and , A. F. Michael. 1990. Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome. J. Lab. Clin. Med. 116: 508– 515.
21.
Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680– 685.
22.
Lowry, O. H.,, N. J. Rosebrough,, A. L. Farr, and , R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265– 275.
23.
Martinez, J. S., and , P. F. Kohler. 1971. Variant “Goodpasture’s syndrome"? The need for immunologic criteria in rapidly progressive glomerulonephritis and hemor-rhagic pneumonitis. Ann. Intern. Med. 75: 67– 76.
24.
McCluskey, R.,, A. Collins, and , J. Niles. 1995. Kidney, p. 109. In R. Colvin,, A. Bhan, and , R. McCluskey (ed.), Diagnostic Immunopathology, 2nd ed. Raven Press, Ltd., New York, N.Y.
25.
McCoy, R. C.,, H. K. Johnson,, W J. Stone, and , C. B. Wilson. 1982. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int. 21: 642– 652.
26.
McPhaul, J. J., Jr., and , F. J. Dixon. 1969. The presence of anti-glomerular basement membrane antibodies in peripheral blood. J. Immunol. 103: 1168– 1175.
27.
McPhaul, J. J., Jr., and , J. D. Mullins. 1976. Glomerulonephritis mediated by antibody to glomerular basement membrane. Immunological, clinical, and histo-pathological characteristics. J. Clin. Investig. 57: 351– 361.
28.
Niles, J. L.,, E. P. Bottinger,, G. R. Saurina,, K. J. Kelly,, G. Pan,, A. B. Collins, and , R. T. McCluskey. 1996. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch. Intern. Med. 156: 440– 445.
29.
Niles, J. L.,, G. L. Pan,, A. B. Collins,, T. Shannon,, S. Skates,, R. Fienberg,, M. A. Arnaout, and , R. T. McCluskey. 1991. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J. Am. Soc. Nephrol. 2: 27– 36.
30.
Olson, D. L.,, S. K. Anand,, B. H. Landing,, E. Heuser,, C. M. Grushkin, and , E. Lieberman. 1980. Diagnosis of hereditary nephritis by failure of glomeruli to bind anti-glomerular basement membrane antibodies. J. Pediatr. 96: 697– 699.
31.
Pusey, C. D.,, A. Dash,, M. J. Kershaw,, A. Morgan,, A. Reilly,, A. J. Rees, and , C. M. Lockwood. 1987. A single autoantigen in Goodpasture’s syndrome identified by a monoclonal antibody to human glomerular basement membrane. Lab. Investig. 56: 23– 31.
32.
Saxena, R.,, P. Bygren,, R. Butkowski, and , J. Wieslander. 1989. Specificity of kidney-bound antibodies in Goodpasture’s syndrome. Clin. Exp. Immunol. 78: 31– 36.
33.
Segelmark, M.,, R. Butkowski, and , J. Wieslander. 1990. Antigen restriction and IgG subclasses among anti-GBM autoantibodies. Nephrol. Dial. Transplant. 5: 991– 996.
34.
Timpl, R. 1989. Structure and biological activity of basement membrane proteins. Eur. J. Biochem. 180: 487– 502.
35.
Wieslander, J.,, J. F. Barr,, R. J. Butkowski,, S. J. Edwards,, P. Bygren,, D. Heinegard, and , B. G. Hudson. 1984. Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen. Proc. Natl. Acad. Sci. USA 81: 3838– 3842.
36.
Wieslander, J.,, P. Bygren, and , D. Heinegard. 1984. Isolation of the specific glomerular basement membrane antigen involved in Goodpasture syndrome. Proc. Natl. Acad. Sci. USA 81: 1544– 1548.
37.
Wiik, A. 2002. Antineutrophil cytoplasmic antibodies (ANCAs) and ANCA testing, p. 981– 986. In N. R. Rose,, R. G. Hamilton, and , B. Detrick (ed.), Manual of Clinical Laboratory Immunology, 6th ed. ASM Press, Washington, D.C.
38.
Wilson, C. 1980. Radioimmunoassay for anti-glomerular basement membrane antibodies, p. 376– 380. In N. Rose and , H. Friedman (ed.), Manual of Clinical Immunology, 2nd ed. American Society for Microbiology, Washington, D.C.
39.
Wilson, C. B., and , F. J. Dixon. 1973. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 3: 74– 89.
40.
Zhou, J.,, D. F. Barker,, S. L. Hostikka,, M. C. Gregory,, C. L. Atkin, and , K. Tryggvason. 1991. Single base mutation in alpha 5(IV) collagen chain gene converting a conserved cysteine to serine in Alport syndrome. Genomics 9: 10– 18.
41.
Zhou, J.,, S. L. Hostikka,, L. T. Chow, and , K. Tryggvason. 1991. Characterization of the 3’ half of the human type IV collagen alpha 5 gene that is affected in the Alport syndrome. Genomics 9: 1– 9.
42.
Zhou, J.,, T. Mochizuki,, H. Smeets,, C. Antignac,, P. Laurila,, A. de Paepe,, K. Tryggvason, and , S. T. Reeders. 1993. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science 261: 1167– 1169.